WO2005045010A1 - Method of isolating and culturing mesenchymal stem cell derived from umbilical cord blood - Google Patents
Method of isolating and culturing mesenchymal stem cell derived from umbilical cord blood Download PDFInfo
- Publication number
- WO2005045010A1 WO2005045010A1 PCT/KR2004/002715 KR2004002715W WO2005045010A1 WO 2005045010 A1 WO2005045010 A1 WO 2005045010A1 KR 2004002715 W KR2004002715 W KR 2004002715W WO 2005045010 A1 WO2005045010 A1 WO 2005045010A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- umbilical cord
- cord blood
- mesenchymal stem
- stem cells
- monocytes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
Definitions
- the present invention relates to a method for isolating and culturing a mesenchymal stem cell using umbilical cord blood that is most ideal for a cell therapy.
- Mesenchymal stem cells refer to primitive cells that are able to differentiate into bone, cartilage, adipose, nerve and muscle, for example, and are known as being contained in a large amount in bone marrow.
- mesenchymal stem cells are presently isolated from bone marrow and then studied for certain purposes or widely used in clinical trials for a variety of diseases. Although it is easy to obtain mesenchymal stem cells from bone marrow, there are difficulty in acquisition of the bone marrow and further, difficulty to solve problems associated with an immunological rejection reaction occurring when implanting stem cells to others, at present.
- umbilical cord blood is relatively easy to obtain compared with bone marrow, and also, where great numbers of umbilical cord blood units are secured, it is possible to employ umbilical cord blood stem cells that are identical with or most similar to histocompatibility genes of patients and thereby it is possible to solve problems associated with immunological rejection.
- umbilical cord blood stem cells that are identical with or most similar to histocompatibility genes of patients and thereby it is possible to solve problems associated with immunological rejection.
- mesenchymal stem cells from umbilical cord blood, as compared to bone marrow and thereby there is difficulty in study and clinical applications.
- Conventionally, as a method for isolating very minute amounts of mesenchymal stem cells contained in umbilical cord blood there has been largely used a method involving separating a leucocyte layer using a density gradient centrifugation method and then culturing cells.
- 5,197,985 is directed to a method for inducing human bone marrow-derived mesenchymal stem cells to differentiate into bone- forming cells, comprising: providing human bone marrow-derived mesenchymal stem cells that have been isolated, purified and culturally expanded from a bone marrow specimen by adding the bone marrow specimen to a medium which contains factors which stimulate mesenchymal cell growth without differentiation and allows, when cultured, for selective adherence of only the mesenchymal stem cells to a substrate surface; applying the isolated, purified and culturally expanded human bone marrow-derived mesenchymal stem cells to a porous carrier; and, implanting the porous carrier containing the culturally expanded human bone marrow-derived mesenchymal stem cells into an environment containing factors necessary for differentiating the human mesenchymal stem cells into bone cells, wherein said porous carrier comprises hydroxyapatite and tricalcium phosphate and wherein said medium is comprised of BGJ b medium with fetal bovine serum (
- 5,486,359 discloses isolated human mesenchymal stem cells which can differentiate into cells of more than one tissue type (for example, bone, cartilage, muscle or marrow stroma), a method for isolating, purifying and culturally expanding human mesenchymal stem cells, and characterization of and uses, particularly research reagent, diagnostic and therapeutical uses for such cells.
- tissue type for example, bone, cartilage, muscle or marrow stroma
- mesenchymal stem cells are derived from bone marrow and cultured in BGJ b medium containing fetal bovine serum.
- the present invention has been made in view of the above problems raised in culturing mesenchymal stem cells, and it is an object of the present invention to provide a reproducible method for isolating and culturing mesenchymal stem cells, in which umbilical cord blood-derived mesenchymal stem cells can be obtained without the loss of cells in the course of density gradient centrifugation.
- a method for isolating and culturing mesenchymal stem cells from umbilical cord blood comprising the steps of: adding an anti-coagulant to the umbilical cord blood having a volume of more than 45 ml per unit, which is pure umbilical cord blood obtained within 24 hours after parturition; diluting the resulting mixture of the anti-coagulant and umbilical cord blood with an alpha-minimum essential medium (aMEM), followed by centrifugation to harvest monocytes; and subjecting the obtained monocytes into suspension culture in the aMEM medium containing Stem Cell Factor, GM-CSF (granulocyte-macrophage colony- stimulating factor), G-CSF (granulocyte colony-stimulating factor), IL-3 (interleukin-3) and IL-6 (interleukin-6).
- GM-CSF granulocyte-macrophage colony- stimulating factor
- G-CSF granulocyte colony-stimulating factor
- IL-3 interleukin
- the present invention provides a reproducible method for isolating and culturing mesenchymal stem cells from umbilical cord blood units within 24 hours which was harvested after parturition from a woman delivered of a child. That is, it is intended to contribute to treatment of intractable diseases using umbilical cord blood, by finding out optimum conditions for isolating and culturing mesenchymal stem cells from umbilical cord blood relatively lacking the number of cells.
- the present invention is completed by diluting umbilical cord blood with 2-fold volume of aMEM medium, followed by centrifugation so as to harvest a monocyte layer, and then culturing monocytes in the aMEM medium to which cell growth factors, Stem Cell Factor, GM-CSF, G-CSF, IL-3 and IL-6 were added, thereby making it possible to secure primitive mesenchymal stem cells and improve a success rate of cell culture up to about 90% from less than of 10% obtained in a conventional method.
- Figs. 1 through 5 are photographs (X 100) showing results after culturing an umbilical cord blood mesenchymal stem cell line, for 5, 7, 10, 15 and 25 days, in accordance with a method of the present invention. Best Mode
- the umbilical cord blood was diluted with two-fold volume of aMEM (alpha-minimum essential medium, Jeil Biotech Services, Korea), transferred to a 50 ml Falcon tube and centrifuged at 300xg, at room temperature for 10 min. The separated buffy coat layer was collected, diluted again with two-fold volume of aMEM, overlapped on Ficoll-Hypaque and centrifuged at 300xg, at room temperature for 30 min.
- Ficoll-Hypaque which is a polymer of Ficoll (a polymer of sucrose) and Hypaque (sodium ditrizoate)
- Ficoll-Hypaque which is a polymer of Ficoll (a polymer of sucrose) and Hypaque (sodium ditrizoate)
- Ficoll-Hypaque has a specific gravity of 1.077 g/ ⁇ n£, which is heavier than that of monocytes, but lighter than that of red blood cells, thus making it possible to separate from each other by specific gravity difference therebetween. That is, when blood is placed on Ficoll-Hypaque and centrifuged, monocytes are gathered on Ficoll-Hypaque. Monocytes obtained by such a density gradient centrifugation method were placed again in a washing aMEM in which additives had not been mixed and centrifuged at 200xg, for 10 min, and thereafter, aMEM was discarded and washed, except for cells sedimented at the bottom of the Falcon tube.
- aMEM was added thereto once again, centrifuged at 200xg for 10 min, and thereafter, aMEM was discarded and washed one more time, except for cells sedimented at the bottom of the Falcon tube.
- an antibiotic 1000 U/mt penicillin G, 1000 ⁇ g/ml Streptomycin sulfate, Gibco-BRL
- an anti-fungal agent (0.25 //g/iii£ Amphotericin B)
- 2 mM of Glutamine (Sigma) were added 20% fetal bovine serum (FBS, Jeil Biotech Services, Korea) and as cell growth factors, Stem Cell Factor (50 ng/m£), GM-CSF (granulocyte-macrophage colony-stimulating factor; 10 ng/mt), G-CSF (granulocyte colony-stimulating factor; 10 ng/m ), IL-3 (interleukin-3; 10 ng/ml) and IL-6 (interle
- Figs. 1 through 5 are photographs (X 100) showing results observed after culturing an umbilical cord blood mesenchymal stem cell line, for 5, 7, 10, 15 and 25 days, in accordance with a method of the present invention. As can be seen, when monocytes isolated from umbilical cord blood were cultured, cells adhering to and growing at the bottom of the flask were observed 5 days after culturing and on day 7, cells formed colonies and then grown to cells having various shapes.
- Example 2 Characterization of a cell surface antigen of cultured mesenchymal stem cells
- FACS fluorescence activated cell sorting
- CD34, CD45 and CD 14 which are characteristic indicators of hematopoietic stem cells, showed negative reactions
- CD 166 showed a weak positive reaction. This fact is interpreted as showing that cells isolated and cultured in accordance with the present invention are mesenchymal stem cells.
- Example 3 Comparison of success rate of mesenchymal stem cell culture 50 units of umbilical cord blood were cultured according to a conventional method and the method of the present invention, respectively, and success rates of cell culture were compared therebetween. The results are shown in Table 2 below. Specifically, in the conventional method, umbilical cord blood was used in stem cell culturing, without criteria on an amount of umbilical cord blood to be used and a period from parturition to harvesting. Further, the conventional method did not include cell growth factors in a culture medium, and except for that point, an isolating process of cells was performed similar to the method in accordance with the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/579,070 US7704739B2 (en) | 2003-11-11 | 2004-10-25 | Method of isolating and culturing mesenchymal stem cell derived from umbilical cord blood |
CN200480033035XA CN1878860B (en) | 2003-11-11 | 2004-10-25 | Method of isolating and culturing mesenchymal stem cell derived from umbilical cord blood |
DE602004027754T DE602004027754D1 (en) | 2003-11-11 | 2004-10-25 | METHOD OF ISOLATING AND CULTURING FROM CORDIAL BLOOD OF OBTAINED MESENCHYMAL STEM CELLS |
EP04793573A EP1687414B1 (en) | 2003-11-11 | 2004-10-25 | Method of isolating and culturing mesenchymal stem cell derived from umbilical cord blood |
AT04793573T ATE471368T1 (en) | 2003-11-11 | 2004-10-25 | METHOD FOR ISOLATION AND CULTIVATION OF MESENCHYMAL STEM CELLS OBTAINED FROM UMBILICAL CORD BLOOD |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030079362A KR100560340B1 (en) | 2003-11-11 | 2003-11-11 | Method of isolating and culturing mesenchymal stem cell derived from umbilical cord blood |
KR10-2003-0079362 | 2003-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005045010A1 true WO2005045010A1 (en) | 2005-05-19 |
Family
ID=36642516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2004/002715 WO2005045010A1 (en) | 2003-11-11 | 2004-10-25 | Method of isolating and culturing mesenchymal stem cell derived from umbilical cord blood |
Country Status (7)
Country | Link |
---|---|
US (1) | US7704739B2 (en) |
EP (1) | EP1687414B1 (en) |
KR (1) | KR100560340B1 (en) |
CN (1) | CN1878860B (en) |
AT (1) | ATE471368T1 (en) |
DE (1) | DE602004027754D1 (en) |
WO (1) | WO2005045010A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006071011A1 (en) * | 2004-12-30 | 2006-07-06 | Hoon Han | Composition for treating baldness with stem cell derived from umbilical cord blood |
WO2007024036A1 (en) * | 2005-08-26 | 2007-03-01 | Seoul National University Industry Foundation | Multipotent stem cells isolated from umbilical cord blood and the cellular therapeutic agent comprisin the same for treating ischemic disease |
KR100812544B1 (en) * | 2006-10-19 | 2008-03-13 | 재단법인서울대학교산학협력재단 | Multipotent Stem Cells Isolated from Umbilical Cord Blood and the Cellular Therapeutic Agent Comprising the Same for Treating Ischemic Disease |
WO2008050962A1 (en) * | 2006-10-24 | 2008-05-02 | College Of Medicine Pochon Cha University Industry-Academic Cooperation Foundation | Composition for in vivo transplantation for treatment of human cervical cancer comprising mononuclear cells derived from umbilical cord blood |
CN101331225B (en) * | 2005-12-02 | 2012-06-13 | 财团法人首尔大学校产学协力财团 | Multipotent adult stem cells having an ability of Oct4 expression derived from umbilical cord blood and method for preparing the same |
CN102559590A (en) * | 2012-01-16 | 2012-07-11 | 遵义医学院附属医院 | Method for sequential culture of human umbilical cord blood mesenchymal stem cells by using two culture media |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7311905B2 (en) * | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
US20080152629A1 (en) * | 2000-12-06 | 2008-06-26 | James Edinger | Placental stem cell populations |
WO2004069172A2 (en) | 2003-01-30 | 2004-08-19 | The Government of the United States of America as represented by the Department of Veterans Affairs | Multilineage-inducible cells and uses thereof |
CN100377165C (en) * | 2003-04-24 | 2008-03-26 | 皇家飞利浦电子股份有限公司 | Non-invasive left ventricular volume determination |
KR100534215B1 (en) * | 2003-11-11 | 2005-12-08 | (주)히스토스템 | Method of isolating and culturing mesenchymal stem cell derived from cryopreserved umbilical cord blood |
KR100679950B1 (en) * | 2005-05-18 | 2007-02-08 | 한훈 | Composition for cell?therapy of amyotrophic lateral sclerosis using mannitol and stem cell derived from umbilical cord blood |
NZ597304A (en) * | 2005-10-13 | 2013-06-28 | Anthrogenesis Corp | Immunomodulation using placental stem cells |
EP1976977B1 (en) | 2005-12-29 | 2015-07-08 | Anthrogenesis Corporation | Placental stem cell populations |
KR100791487B1 (en) * | 2006-05-29 | 2008-01-03 | 연세대학교 산학협력단 | A method for isolating and culturing mesenchymal stem cell derived from umbilical cord blood |
CN101657206B (en) | 2007-02-12 | 2013-07-03 | 人类起源公司 | Treatment of inflammatory diseases using placental stem cells |
KR100888924B1 (en) * | 2007-06-04 | 2009-03-16 | 주식회사 제이비줄기세포연구소 | A distinguishing method of fibroblast from mesenchymal stem cell derived from human umbilical cord blood |
CN101878034B (en) | 2007-09-28 | 2013-11-20 | 细胞基因细胞疗法公司 | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
KR101077042B1 (en) * | 2008-03-28 | 2011-10-26 | 경희대학교 산학협력단 | Use of CD45+ cell or CD45+ cell-conditioned medium for facilitating proliferation of mesenchymal stem cells |
CA2734237C (en) * | 2008-08-20 | 2019-07-02 | Anthrogenesis Corporation | Treatment of stroke using isolated placental cells |
KR20200011604A (en) | 2008-08-20 | 2020-02-03 | 안트로제네시스 코포레이션 | Improved cell composition and methods of making the same |
AU2009283161A1 (en) | 2008-08-22 | 2010-02-25 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
US8367409B2 (en) | 2008-11-19 | 2013-02-05 | Anthrogenesis Corporation | Amnion derived adherent cells |
CN102822330A (en) | 2010-01-26 | 2012-12-12 | 人类起源公司 | Treatment of bone-related cancers using placental stem cells |
SI2556145T1 (en) | 2010-04-07 | 2017-01-31 | Anthrogenesis Corporation | Angiogenesis using placental stem cells |
WO2011127113A1 (en) | 2010-04-08 | 2011-10-13 | Anthrogenesis Corporation | Treatment of sarcoidosis using placental stem cells |
WO2012009422A1 (en) | 2010-07-13 | 2012-01-19 | Anthrogenesis Corporation | Methods of generating natural killer cells |
CN102154200B (en) * | 2010-12-13 | 2012-10-03 | 中国人民解放军第三○二医院 | Preparation and storage of mesenchymal stem cells for clinical treatment |
US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
CN113559126A (en) | 2011-06-01 | 2021-10-29 | 人类起源公司 | Treatment of pain using placental stem cells |
US8940294B2 (en) | 2012-03-02 | 2015-01-27 | Tissuetech, Inc. | Methods of isolating and culturing stem cells |
CN102876630B (en) * | 2012-11-05 | 2015-02-18 | 东南大学 | Method for efficiently separating and expanding mesenchymal stem cells in human umbilical cord blood |
EP3622960A1 (en) | 2013-02-05 | 2020-03-18 | Celularity, Inc. | Natural killer cells from placenta |
CN103451151B (en) * | 2013-06-19 | 2016-01-20 | 武汉道培胎盘干细胞生物技术有限公司 | A kind of method of cultivator umbilical cord mesenchymal stem cells |
CN103555663B (en) * | 2013-11-19 | 2015-07-22 | 武汉道培胎盘干细胞生物技术有限公司 | Method for cultivating human amniotic mesenchymal stem cells |
KR101642776B1 (en) * | 2014-04-09 | 2016-07-29 | 대한민국 | Antibiotic composition including stem cell |
RU2644650C2 (en) | 2014-12-01 | 2018-02-13 | Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" | Stem cell material and method for its reception |
RU2708329C2 (en) | 2016-05-31 | 2019-12-05 | Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" | Stem cell material, compositions and methods of use |
CN111643526A (en) * | 2020-07-14 | 2020-09-11 | 贵州金元泰生物科技有限公司 | Mesenchymal stem cell preparation for delaying ovarian aging and preventing and treating senile dementia and depression |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5197985A (en) * | 1990-11-16 | 1993-03-30 | Caplan Arnold I | Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells |
US5486359A (en) * | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
US6335195B1 (en) * | 1997-01-28 | 2002-01-01 | Maret Corporation | Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1564864A (en) * | 2001-08-07 | 2005-01-12 | 麒麟麦酒株式会社 | Process for preparing hematopoietic stem cells |
-
2003
- 2003-11-11 KR KR1020030079362A patent/KR100560340B1/en active IP Right Grant
-
2004
- 2004-10-25 AT AT04793573T patent/ATE471368T1/en active
- 2004-10-25 US US10/579,070 patent/US7704739B2/en not_active Expired - Fee Related
- 2004-10-25 WO PCT/KR2004/002715 patent/WO2005045010A1/en active Application Filing
- 2004-10-25 EP EP04793573A patent/EP1687414B1/en not_active Not-in-force
- 2004-10-25 CN CN200480033035XA patent/CN1878860B/en not_active Expired - Fee Related
- 2004-10-25 DE DE602004027754T patent/DE602004027754D1/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5197985A (en) * | 1990-11-16 | 1993-03-30 | Caplan Arnold I | Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells |
US5486359A (en) * | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
US6335195B1 (en) * | 1997-01-28 | 2002-01-01 | Maret Corporation | Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
Non-Patent Citations (2)
Title |
---|
HOU L. ET AL.: "Inuction of umbilical cord blood mesenchymal stem cell into neuron-like cells in vitro", INT. J. HEMATOL., vol. 78, no. 3, October 2003 (2003-10-01), pages 256 - 261, XP009027406 * |
ROONEY P. ET AL.: "Blood vessels & mesenchymal cells: can they make better bone?", EUROPEAN CELLS AND MATERIALS, vol. 5, no. SUPPL.2, June 2003 (2003-06-01), pages 8, XP008069571 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006071011A1 (en) * | 2004-12-30 | 2006-07-06 | Hoon Han | Composition for treating baldness with stem cell derived from umbilical cord blood |
WO2007024036A1 (en) * | 2005-08-26 | 2007-03-01 | Seoul National University Industry Foundation | Multipotent stem cells isolated from umbilical cord blood and the cellular therapeutic agent comprisin the same for treating ischemic disease |
CN101331225B (en) * | 2005-12-02 | 2012-06-13 | 财团法人首尔大学校产学协力财团 | Multipotent adult stem cells having an ability of Oct4 expression derived from umbilical cord blood and method for preparing the same |
KR100812544B1 (en) * | 2006-10-19 | 2008-03-13 | 재단법인서울대학교산학협력재단 | Multipotent Stem Cells Isolated from Umbilical Cord Blood and the Cellular Therapeutic Agent Comprising the Same for Treating Ischemic Disease |
WO2008050962A1 (en) * | 2006-10-24 | 2008-05-02 | College Of Medicine Pochon Cha University Industry-Academic Cooperation Foundation | Composition for in vivo transplantation for treatment of human cervical cancer comprising mononuclear cells derived from umbilical cord blood |
CN102559590A (en) * | 2012-01-16 | 2012-07-11 | 遵义医学院附属医院 | Method for sequential culture of human umbilical cord blood mesenchymal stem cells by using two culture media |
Also Published As
Publication number | Publication date |
---|---|
CN1878860A (en) | 2006-12-13 |
KR20050045325A (en) | 2005-05-17 |
US20070092967A1 (en) | 2007-04-26 |
ATE471368T1 (en) | 2010-07-15 |
EP1687414B1 (en) | 2010-06-16 |
DE602004027754D1 (en) | 2010-07-29 |
CN1878860B (en) | 2012-05-30 |
KR100560340B1 (en) | 2006-03-14 |
EP1687414A4 (en) | 2007-09-12 |
EP1687414A1 (en) | 2006-08-09 |
US7704739B2 (en) | 2010-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1687414B1 (en) | Method of isolating and culturing mesenchymal stem cell derived from umbilical cord blood | |
US5965436A (en) | Method of isolating mesenchymal stem cells associated with isolated megakaryocytes by isolating megakaryocytes | |
WO1998020731A9 (en) | Msc-megakaryocyte precursor composition and method of isolating mscs associated with isolated megakaryocytes by isolating megakaryocytes | |
JP2021045176A (en) | Compositions and Methods for Inducing Activation of Immature Monocytic Dendritic Cells | |
EP2308964B1 (en) | Culturing method of mesenchymal stem cell | |
EP1687415B1 (en) | Method of isolating and culturing mesenchymal stem cell derived from cryopreserved umbilical cord blood | |
KR20080015033A (en) | Method of forming dendritic cells from embryonic stem cells | |
EP2881462B1 (en) | Method for obtaining monocytes or nk cells | |
EP1687411A2 (en) | Hematopoietic stem cell identification and isolation | |
JP2002543829A (en) | Ex vivo expansion of mammalian hematopoietic stem cells | |
EP2610337B1 (en) | Method for expanding blood adult stem cells | |
CN110055219B (en) | Method for preparing heterogeneous hematopoietic stem and progenitor cells by using non-mobilized peripheral blood | |
KR100818215B1 (en) | Method for preparing t-cell progenitor from cd34 positive stem cell | |
CN110862961A (en) | Preparation method of bone marrow mesenchymal stem cells | |
JP2011239701A (en) | Method for culturing dendritic cell | |
JP6426767B2 (en) | Method for culturing dendritic cells | |
Zou et al. | Isolation, culture and propagation of dendritic cells | |
CN117126809A (en) | Kit for in vitro induction of NK cell amplification and method for in vitro induction of NK cell amplification | |
EP1795589A1 (en) | Method for the direct culture of dendritic cells without a preceding centrifugation step | |
KR101149007B1 (en) | Method for Preparing Hematopoietic Stem Cells Having Improved Engraftment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480033035.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004793573 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007092967 Country of ref document: US Ref document number: 10579070 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004793573 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10579070 Country of ref document: US |